What Site Feasibility Actually Measures

Site feasibility is the process sponsors and CROs use to decide which clinical trial sites are realistically capable of meeting a study's enrollment, quality, and timeline requirements before a single Clinical Trial Agreement is signed. For a research site or site network, understanding exactly what feasibility teams are scoring, and why, is the difference between a feasibility questionnaire that turns into a signed contract and one that quietly disappears into a sponsor's site database.

Feasibility assessment has moved well beyond a simple investigator CV and a checklist of GCP training certificates. Modern feasibility questionnaires typically evaluate a site across five dimensions: patient population and addressable enrollment, operational infrastructure, investigator and staff experience, regulatory and quality history, and increasingly, data and technology readiness.

Patient Population: The Math Sponsors Actually Run

The single most common reason a site fails feasibility isn't investigator qualification or facility quality, it's an enrollment number that doesn't hold up under scrutiny. Sponsors run their own models estimating how many eligible patients exist within a site's catchment area, often using claims data, EHR penetration statistics, and epidemiological prevalence rates for the target indication. When a site's self-reported enrollment projection is significantly higher than what the sponsor's external model predicts, that gap is a red flag, not a negotiating position.

Sites that perform well on this dimension typically provide:

  • A realistic screen-to-enroll ratio based on prior studies in the same or an adjacent indication, not an optimistic best case
  • A description of how patients are identified, whether through EHR queries, referral networks, embedded clinic populations, or advertising, since sponsors weight organic identification methods differently than paid recruitment
  • Evidence of competing trial awareness, showing the site understands what other studies might be drawing from the same patient pool

Operational Infrastructure: Speed Is a Feature

Feasibility teams increasingly weight site activation timelines as heavily as raw enrollment capacity, because a site that enrolls well but activates slowly can still blow a study timeline. Metrics that matter here include:

  • Average time from regulatory document request to submission
  • Historical IRB approval turnaround, including whether the site uses a central IRB or local IRB, since central IRB reliance generally speeds activation
  • Contract and budget negotiation turnaround, an area where sites with a standing Master Clinical Trial Agreement or Master Confidentiality and Disclosure Agreement (MCDA) with a sponsor or CRO have a measurable advantage
  • Monitoring visit responsiveness, since CRAs report site cooperation and document readiness back to the sponsor after every visit, and that reporting directly informs future site selection

Investigator and Staff Experience, Beyond the CV

A principal investigator's CV still matters, but feasibility teams have gotten more sophisticated about what experience actually predicts good performance. A PI with twenty studies listed but a history of protocol deviations or slow enrollment is a weaker feasibility candidate than a PI with five studies and a clean quality record. What sponsors are actually looking for:

  • Therapeutic area-specific experience, since a cardiology PI running a first oncology study carries more risk than one with a track record in the target indication
  • Sub-investigator depth, since a single-PI site is a single point of failure if that physician becomes unavailable mid-study
  • Coordinator continuity, because staff turnover during a study is one of the strongest predictors of enrollment and data quality problems, and sponsors have started asking directly about staff tenure

Regulatory and Quality History

Sponsors and CROs increasingly cross-reference sites against FDA inspection history, prior audit findings, and CAPA (corrective and preventive action) history when it's available. A clean regulatory history is table stakes; sites that can proactively summarize their quality systems, including how protocol deviations are logged, reviewed, and prevented from recurring, present a materially stronger feasibility package than sites that simply state "no major findings."

Data and Technology Readiness

This is the newest feasibility dimension, and it's growing quickly in weight as more studies incorporate decentralized elements, electronic patient-reported outcomes (ePRO), wearable devices, or direct data capture. Feasibility questionnaires now regularly ask about:

  • EDC (electronic data capture) system experience and connectivity
  • Capacity to support remote or hybrid visit models
  • Site-level IT infrastructure for wearable device data transmission
  • Experience with risk-based monitoring and remote source data verification

Sites that can answer these questions concretely, rather than defaulting to "we can accommodate whatever is needed," score measurably better with sponsors running technology-forward protocols.

Turning Feasibility Weaknesses Into a Development Plan

Not every site or network will score well across all five dimensions immediately, and that's a normal starting point rather than a disqualifying one. The sites that improve their win rate over time treat feasibility scoring as diagnostic information:

  1. Identify which dimension consistently produces the most feasibility declines (commonly enrollment projections or activation speed)
  2. Build a specific operational fix, such as a standing MCDA program to cut contract turnaround, or a referral network expansion to strengthen enrollment projections
  3. Re-test the fix against the next feasibility cycle and track the change in win rate

The Feasibility Questionnaire as a Relationship Tool

It's worth remembering that a feasibility questionnaire isn't only a gate, it's also one of the few structured touchpoints a site gets with a sponsor's clinical operations team before a study is awarded. A thorough, honest, well-organized feasibility response, submitted on time and with verified data, builds credibility even for studies where the site isn't ultimately selected. Sponsors keep records of site responsiveness and honesty across studies, and that reputation compounds. Sites that consistently submit strong, accurate feasibility packages get invited to more feasibility rounds over time, even in indications where they haven't previously been selected, simply because the sponsor trusts the data the site provides.

How Feasibility Scoring Actually Gets Weighted

Sponsors and CROs vary in exactly how they weight each feasibility dimension, but most modern feasibility scoring models follow a broadly similar pattern, and understanding it helps a site prioritize where to invest improvement effort:

  • Enrollment feasibility typically carries the heaviest single weight, often 30 to 40 percent of a composite score, because it is the single strongest predictor of whether a study hits its timeline
  • Operational readiness, including activation speed and contract turnaround, usually accounts for another 20 to 25 percent, reflecting how much a slow site can delay an entire multi-site study
  • Investigator and staff experience typically contributes 15 to 20 percent, weighted more heavily in complex or first-in-class studies where clinical judgment matters more
  • Quality and regulatory history usually sits around 10 to 15 percent as a gating factor rather than a differentiator, meaning a poor score here can disqualify a site even if other dimensions are strong
  • Data and technology readiness has grown from a minor consideration to 10 to 15 percent in recent cycles, particularly for protocols with decentralized elements

A site that understands this weighting can make a more rational decision about where to invest limited improvement resources. For most sites, fixing enrollment projection accuracy and activation speed produces a larger feasibility score improvement than, for example, investing heavily in wearable device infrastructure for indications where that technology isn't yet commonly required.

The Feasibility Questionnaire Itself: Getting the Details Right

Beyond the underlying data, the mechanics of how a feasibility questionnaire is completed affect scoring more than most sites realize. Common, avoidable mistakes include:

  • Inconsistent numbers across sections, such as a screening rate in one section that doesn't mathematically reconcile with the enrollment projection in another, which signals a rushed or careless response to an experienced feasibility reviewer
  • Generic answers to specific questions, particularly around patient identification methodology, where "we use multiple recruitment channels" reads as a non-answer compared to a specific description of EHR query criteria, referral partnerships, or advertising channels actually used
  • Missing or outdated site documents, such as an expired CV, outdated financial disclosure form, or a lapsed CLIA certificate, any of which can stall a feasibility response regardless of how strong the clinical case is
  • Late submission, which is scored negatively at almost every sponsor and CRO regardless of how strong the eventual answer is, since responsiveness is itself a proxy metric for how the site will behave once a study is active

Maintaining a feasibility-ready document library, updated on a set schedule rather than reactively when a questionnaire arrives, removes most of these avoidable errors and materially shortens response time.

A Practical Pre-Feasibility Readiness Checklist

Sites that want to shorten their response time and strengthen their feasibility submissions benefit from maintaining a standing readiness checklist, reviewed on a quarterly cycle rather than assembled under pressure when a questionnaire arrives:

  • Current, signed investigator and sub-investigator CVs and financial disclosure forms for every active study team member
  • Updated screen-to-enroll and enrollment timeline data for each active therapeutic area, refreshed after every completed study
  • A current summary of IRB relationship and typical approval turnaround time
  • A one-page description of the site's patient identification methodology by therapeutic area, ready to adapt to a specific protocol
  • Current CLIA certification, laboratory accreditation, and any relevant facility certifications
  • A summary of any prior FDA inspection or sponsor audit findings, along with the corrective actions taken
  • A description of EDC systems and decentralized trial technology experience, updated as new studies add new platform experience

Sites that treat this list as a living document, assigning clear ownership for keeping each item current, consistently turn around feasibility questionnaires faster and with fewer last-minute scrambles than sites that reconstruct this information from scratch every time a new opportunity arrives.

Frequently Asked Questions on Site Feasibility

What is the difference between a feasibility questionnaire and a site qualification visit?

A feasibility questionnaire is typically a written or online survey completed early in site selection, used to screen a broad list of candidate sites down to a shortlist. A site qualification visit (SQV), whether conducted in person or remotely, is a deeper evaluation of the shortlisted sites, often including a facility review, regulatory document audit, and direct conversation with the principal investigator and study team, and it happens after feasibility screening rather than instead of it.

How often should a site update its feasibility data library?

Quarterly is a reasonable minimum for enrollment and operational metrics, with an immediate update whenever a significant change occurs, such as a new PI joining, a change in IRB, or completion of a study that materially affects screen-to-enroll data in a given therapeutic area.

Does a site's size disadvantage it in feasibility scoring compared to larger academic medical centers?

Not inherently. Sponsors increasingly value community-based and embedded research sites for faster activation, more representative patient populations, and often stronger retention than large academic centers, which can struggle with activation speed and staff turnover due to their scale. Site size matters less than data quality and operational reliability in most modern feasibility scoring models.

What's the most common reason a clinically strong site still loses feasibility rounds?

Slow or incomplete feasibility response turnaround. Sponsors frequently report that sites with strong clinical qualifications lose out simply because a competing site returned a complete, accurate feasibility package faster, since response speed itself is treated as a proxy for how the site will perform once a study is active.

Conclusion

Site feasibility has evolved from a paperwork exercise into a genuinely data-driven evaluation, and sites that understand exactly what's being measured, how it's weighted, and why, put themselves in a materially stronger position to win allocation. The sites winning consistently in 2026 aren't guessing what sponsors want to hear. They're building the operational infrastructure, data discipline, and honest track record that feasibility teams are specifically trained to look for, and they're maintaining that readiness continuously rather than scrambling each time a new questionnaire lands.

The link has been copied!